HYTERA
17.3.2022 08:37:06 CET | Business Wire | Press release
Technology underpins the successful running of all kinds of mega events. Audiences these days are constantly amazed by the top-notch technologies adopted by the Beijing 2022 Winter Olympics and Paralympic Winter Games. Among them, the professional mobile radios (PMR), which support critical communications of the world-class event, have earned wide attention from the public.
As one of the key communication solution suppliers of Beijing 2022 Winter Olympic and Paralympic Winter Games, Hytera provided a certain amount of TETRA devices, PMR-LTE convergent solutions and command & control systems to the security officers and rescue teams during the races. Hytera’s communication technologies also played a major role in the execution of COVID-19 prevention in the Olympic Village.
In fact, besides the global mega sport events, Hytera’s products and solutions are also chosen by industry clients across public safety, transportation, manufacturing, oil and gas as well as the retail and hospitality industries.
Innovation Is in Hytera’s DNA
With continuous investment in technology innovation, Hytera is committed to promoting open communication standards from narrowband to broadband, including TETRA, DMR, PDT and LTE with independent intellectual property rights, which makes it a leading provider of professional communication solutions.
Hytera recently added the H Series to its DMR product portfolios. The new series is built from the ground up on an entirely new technology platform. It is the first of its kind in the industry when it comes to functionality, user experience, and ruggedness, providing efficient and reliable communications to users in security, education industry and customer service roles as well as those working in severe working conditions.
Global Recognition and Partnership Achieved by Hytera
To meet the growing needs of business and critical communication users, Hytera innovatively developed a variety of products and technology solutions. Among them, there are DMR terminals, TETRA terminals, PoC Radios, multimode advanced radios, body worn cameras, command & dispatch and emergency response software that have contributed to the success of users working in the vertical industries, such as public safety, energy, transportation, utility, commercial and operator markets. With audio, visual and data capabilities, Hytera has provided faster, safer, and more versatile connectivity options.
Hytera has showcased its technological strength and achieved global recognition and partnerships. The International Critical Communications Awards (ICAA) awarded Hytera the “Best New LTE or Hybrid Device” for its LTE & TETRA convergent device PTC760, as well as the “Best Use of Critical Communications in Utilities” in recognition of its Hytalk PoC solution for Turkey Electricity Company.
Global partnerships have also validated Hytera’s competence. Hytera played a role in the 2021 FIFA Arab Cup and the 2018 FIFA World Cup with its local partners. Hytera also worked with the security department in Tajikistan during the SCO Summit 2021.
Supporting Communities under Global Challenges
While succeeding in landing international business partnerships, Hytera has also contributed its capacities to tackle global challenges.
To deal with the outbreak of the COVID-19 pandemic, Hytera has actively contributed its capabilities to improve disease prevention. Hytera’s two way radios and pandemic prevention solutions provided fast and reliable non-contact communication to the workers from hospitals, enterprises and security departments around the world to fight against the virus.
As a key player in the critical communications industry, Hytera, empowered by top-performing technologies, will continue to support industrial users, and ensure safer and stronger communication networks worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316006155/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
